Miscellaneous Ocular Agents Archives - MPR

Miscellaneous Ocular Agents

Beovu Labeling Updated With Additional Safety Information

The Food and Drug Administration (FDA) has approved updated labeling for Beovu® (brolucizumab; Novartis) to include additional safety information regarding the risk of retinal vasculitis and retinal vascular occlusion.  Beovu received FDA approval in October 2019 for the treatment of wet age-related macular degeneration (wet AMD). The Warnings and Precautions section has been updated with…